comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 20:44:32 - browse：4417

When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say “brash” in French?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.

For more on what we cover, here’s where you can read Frank’s work; here’s more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： U.K. Biobank has 500,000 peoples' genome sequences available

leisure time

WSS

7 more heat

Vir antibody drug aimed at influenza A fails in clinical trial

Hospitals struggle to profit from CAR

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Hospitals struggle to profit from CAR

Divers poised to search for children washed away in Pennsylvania flash flood

leisure time

comprehensive

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Why Congress must ban federal programs from using QALYs

United colonoscopy coverage change 'may cost lives,' doctors say

Will the market for weight loss drugs really reach $100 billion?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ReNAgade cuts staff seven months after raising $300 million

Activists slam private health insurers over coverage restrictions

Fetal surgery at risk from Dobbs and new abortion restrictions

Hepatitis C has a cure — but many Americans still lack access to it

BIO selects John Crowley as new CEO

hotspot

Tocagen's brain cancer gene therapy trial continues. Investors worry

Why Congress must ban federal programs from using QALYs

Organ aging and disease risk measured by new blood test

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

CDC director unscathed in first congressional testimony

Stanford president faces new allegations over 1999 paper

hotspot

hotspot

leisure time

explore